[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group: The placebo group will receive only aluminum hydroxide adjuvant in the form of deltoid intramuscular injection on days 0 and 14. Placebo is similar to the active vaccine in shape and volume.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group 2: 5 micrograms of antigen protein (Shifa Pharmed Co.) on days 0 and14, which is received intramuscularly (deltoid muscle).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group 1: 3 micrograms of antigen protein (Shifa Pharmed Co.) on days 0 and 14, which is received intramuscularly (deltoid muscle).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "3 micrograms", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 micrograms", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}]